Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Mobilicom to Participate at Enforce Tac 2026, Germany’s Prominent Trade Fair for Security and Defense
-
AMD and Meta Announce Expanded Strategic Partnership to Deploy 6 Gigawatts of AMD GPUs
-
Cipher Digital Provides Fourth Quarter and Full Year 2025 Business Update
-
Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
-
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
-
OROCO COMMENCES PHASE 2 DRILLING
-
Shoals Technologies Group, Inc. Reports Financial Results for Fourth Quarter 2025
-
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
-
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
-
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
-
Shoals Technologies Group and ON.energy to Deploy Critical-Power Systems for Leading AI Data-Center Operator
-
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
-
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
-
iBio to Participate in Upcoming Investor Conferences
-
Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook
-
Balchem Corporation to Participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026
-
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
-
Abaxx Exchange Completes First Physical Delivery Under Gold Singapore Futures Contract
-
OTC Markets Group Welcomes GR Silver Mining Ltd. to OTCQX
-
OTC Markets Group Welcomes Dryden Gold Corp. to OTCQX
-
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
-
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
-
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
-
Avalo Therapeutics to Participate in Upcoming Investor Conferences
-
OTC Markets Group Welcomes Nations Royalty Corp. to OTCQX
-
Option Care Health Announces Financial Results for Fourth Quarter and Full Year 2025
-
Autolus Therapeutics to Participate in Upcoming Investor Conferences
-
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
-
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
-
Indivior to Participate in Upcoming Investor Conferences
-
Full year Trading Update and Notice of Results
-
OR Royalties Announces Acquisition of Additional Royalties on Spring Valley in Nevada
-
Amendment of the Liquidity Agreement with Kepler Cheuvreux
-
Form 8.3 - Picton Property Income Limited
-
YieldMax® ETFs Announces Weekly Distributions for Group 1 ETFs
-
Form 8.3 - LondonMetric Property Plc
-
Form 8.3 - Bluefield Solar Income Fund Ltd
-
Dillard’s, Inc. Reports Fourth Quarter and Fiscal Year Results
-
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
-
Global Indemnity Group 2025 Earnings Release & Conference Call
-
Global Indemnity Group 2025 Earnings Release & Conference Call
-
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
-
Ring Energy Announces Timing of Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
-
CECO Environmental Reports Fourth Quarter and Full Year 2025 Results
-
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
-
CECO Environmental Announces Strategic Combination with Thermon Group, Creating a Global Industrial Leader in Delivering Mission-Critical Environmental and Thermal Solutions
-
Bimergen Advances Redbird 100 MW / 400 MWh Texas Battery Project with JDA Acceptance and Selection of Eos Z3™ Technology
-
Goliath Reports Numerous High-Grade Intercepts Including 24.16 g/t AuEq Over 7.00 Meters, Grade Values Increased By 19.6 % In 56 Gold Equivalent Drill Results, And Expands Vast Stacked Vein System At
-
HSBC Continental Europe: Pre Stabilisation Notice
-
Form 8.3 - [IDOX PLC - 23 02 2026] - (CGWL)
